Indication: Hematological Malignancies
An Open-Label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an anti-CD20 x anti-CD3 Bispecific Antibody, in Patients with Relapsed or Refractory Follicular Lymphoma
Line of Therapy: Must have relapsed or must be refractory to =2 prior lines of systemic therapy, including an anti-CD20 antibody and an alkylating agent
Principal Investigator: Don Stevens, M.D.Norton Cancer Institute
Sponsor: Regeneron Pharmaceuticals, Inc.
Email for more information: Heme-NCIResearch@nortonhealthcare.org